Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3026 IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung

Introduction: Insulin- like growth factor-II messenger RNA- binding protein- 3 (IMP3) is often detected in malignant neoplasm of different sites. Ki-67 proliferative index, although helpful in diagnosing neuroendocrine tumours of lung, has not been recognised as prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bełz A, Stęplewska K, Głogowska- Szeląg J,

Keywords: carcinoid, IMP3, Ki-67, neuroendocrine,

#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis

Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,

Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,